Prolactin fragmentation by trophoblastic matrix metalloproteinases as a possible contributor to peripartum cardiomyopathy and pre-eclampsia

Medical Hypotheses

Volumn 74, Issue 2, 2010, Pages 348-352

  Reuwer, Anne Q ^a   Reuwer, Paul J H M ^b   van der Post, Joris A ^a   Cramer, Maarten J ^c   Kastelein, John J P ^a   Twickler, Marcel Th B ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b Maternity Center   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; CATHEPSIN D; MATRIX METALLOPROTEINASE; OXIDIZED LOW DENSITY LIPOPROTEIN; PROLACTIN; REACTIVE OXYGEN METABOLITE; STAT3 PROTEIN;

APOPTOSIS; ARTICLE; CARDIOMYOPATHY; DRUG MEGADOSE; EMOTIONAL STRESS; ENDOTHELIAL DYSFUNCTION; ETHNICITY; GENETIC PREDISPOSITION; HEART INFARCTION; HORMONAL REGULATION; HUMAN; HYPERPROLACTINEMIA; MATERNAL HYPERTENSION; MILK PRODUCTION; MORTALITY; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PERIPARTUM CARDIOMYOPATHY; PHYSICAL STRESS; PREECLAMPSIA; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROLACTIN BLOOD LEVEL; PROLACTINOMA; PROTEIN DEGRADATION; PSYCHOSIS; RECURRENCE RISK; STROKE;

CARDIOMYOPATHIES; FEMALE; HUMANS; MATRIX METALLOPROTEINASES; MODELS, BIOLOGICAL; PEPTIDE FRAGMENTS; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; PROLACTIN; SIGNAL TRANSDUCTION; TROPHOBLASTS;

EID: 72449121819     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2009.08.029     Document Type: Article

References (47)

1. Ntusi N.B., and Mayosi B.M. Aetiology and risk factors of peripartum cardiomyopathy: A systematic review. Int J Cardiol. 131 (2009) 168-179
2. Cheng M.H., and Wang P.H. Placentation abnormalities in the pathophysiology of preeclampsia. Expert Rev Mol Diagn 9 (2009) 37-49
3. Abboud J., Murad Y., Chen-Scarabelli C., Saravolatz L., and Scarabelli T.M. Peripartum cardiomyopathy: a comprehensive review. Int J Cardiol 118 (2007) 295-303
4. Sliwa K., Fett J., and Elkayam U. Peripartum cardiomyopathy. Lancet 368 (2006) 687-693
5. Elkayam U., Tummala P.P., Rao K., Akhter M.W., Karaalp I.S., Wani O.R., et al. Maternal and fetal outcomes of subsequent pregnancies in women with peripartum cardiomyopathy. N Engl J Med 344 (2001) 1567-1571
6. Campbell S., Rowe J., Jackson C.J., and Gallery E.D. Interaction of cocultured decidual endothelial cells and cytotrophoblasts in preeclampsia. Biol Reprod 71 (2004) 244-252
7. Witlin A.G., Mabie W.C., and Sibai B.M. Peripartum cardiomyopathy: a longitudinal echocardiographic study. Am J Obstet Gynecol 177 (1997) 1129-1132
8. Meads C.A., Cnossen J.S., Meher S., Juarez-Garcia A., ter R.G., Duley L., et al. Methods of prediction and prevention of pre-eclampsia: systematic reviews of accuracy and effectiveness literature with economic modelling. Health Technol Assess 12 (2008) 1-270
9. Georgiopoulos G.A., Stamatelopoulos K.S., Lambrinoudaki I., Lykka M., Kyrkou K., Rizos D., et al. Prolactin and preclinical atherosclerosis in menopausal women with cardiovascular risk factors. Hypertension 54 (2009) 98-105
10. Hilfiker-Kleiner D., Kaminski K., Podewski E., Bonda T., Schaefer A., Sliwa K., et al. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell 128 (2007) 589-600
11. Serri O, Li L, Mamputu JC, Beauchamp MC, Maingrette F, Renier G. The influences of hyperprolactinemia and obesity on cardiovascular risk markers: effects of cabergoline therapy. Clin Endocrinol (Oxf);64:366-370.
12. Yavuz D., Deyneli O., Akpinar I., Yildiz E., Gozu H., Sezgin O., et al. Endothelial function, insulin sensitivity and inflammatory markers in hyperprolactinemic pre-menopausal women. Eur J Endocrinol 149 (2003) 187-193
13. Reuwer A.Q., Nieuwland R., Fernandez I., Goffin V., van Tiel C.M., Schaap M.C., et al. Prolactin does not affect human platelet aggregation or secretion. Thromb Haemost 101 (2009) 1119-1127
14. Rensing K.L., and Twickler T.B. Abdominal aorta aneurysm: an exceptional expression of atherosclerotic disease in type II diabetes. Eur Heart J 29 (2008) 581-582
15. Groote V.R., van den B.G., Pincus S.M., Frolich M., Veldhuis J.D., and Roelfsema F. Increased episodic release and disorderliness of prolactin secretion in both micro- and macroprolactinomas. Eur J Endocrinol 140 (1999) 192-200
16. Le Moli R., Endert E., Fliers E., Mulder T., Prummel M.F., Romijn J.A., et al. Establishment of reference values for endocrine tests. II: Hyperprolactinemia. Neth J Med 55 (1999) 71-75
17. Horseman N.D. Prolactin and mammary gland development. J Mammary Gland Biol Neoplasia 4 (1999) 79-88
18. Grattan D.R., Steyn F.J., Kokay I.C., Anderson G.M., and Bunn S.J. Pregnancy-induced adaptation in the neuroendocrine control of prolactin secretion. J Neuroendocrinol 20 (2008) 497-507
19. Kauppila A., Chatelain P., Kirkinen P., Kivinen S., and Ruokonen A. Isolated prolactin deficiency in a woman with puerperal alactogenesis. J Clin Endocrinol Metab 64 (1987) 309-312
20. Ben-Jonathan N., LaPensee C.R., and LaPensee E.W. What can we learn from rodents about prolactin in humans?. Endocr Rev 29 (2008) 1-41
21. Clapp C., Gonzalez C., Macotela Y., Aranda J., Rivera J.C., Garcia C., et al. Vasoinhibins: a family of N-terminal prolactin fragments that inhibit angiogenesis and vascular function. Front Horm Res 35 (2006) 64-73
22. Corbacho A.M., Martinez de la E.G., and Clapp C. Roles of prolactin and related members of the prolactin/growth hormone/placental lactogen family in angiogenesis. J Endocrinol 173 (2002) 219-238
23. Clapp C., and Weiner R.I. A specific, high affinity, saturable binding site for the 16-kilodalton fragment of prolactin on capillary endothelial cells. Endocrinology 130 (1992) 1380-1386
24. Gonzalez C., Corbacho A.M., Eiserich J.P., Garcia C., Lopez-Barrera F., Morales-Tlalpan V., et al. 16K-prolactin inhibits activation of endothelial nitric oxide synthase, intracellular calcium mobilization, and endothelium-dependent vasorelaxation. Endocrinology 145 (2004) 5714-5722
25. Clapp C., Aranda J., Gonzalez C., Jeziorski M.C., and Martinez de la E.G. Vasoinhibins: endogenous regulators of angiogenesis and vascular function. Trends Endocrinol Metab 17 (2006) 301-307
26. Hilfiker-Kleiner D., Meyer G.P., Schieffer E., Goldmann B., Podewski E., Struman I., et al. Recovery from postpartum cardiomyopathy in 2 patients by blocking prolactin release with bromocriptine. J Am Coll Cardiol 50 (2007) 2354-2355
27. Negoro S., Kunisada K., Fujio Y., Funamoto M., Darville M.I., Eizirik D.L., et al. Activation of signal transducer and activator of transcription 3 protects cardiomyocytes from hypoxia/reoxygenation-induced oxidative stress through the upregulation of manganese superoxide dismutase. Circulation 104 (2001) 979-981
28. Adiguzel E., Ahmad P.J., Franco C., and Bendeck M.P. Collagens in the progression and complications of atherosclerosis. Vasc Med 14 (2009) 73-89
29. Forster O., Hilfiker-Kleiner D., Ansari A.A., Sundstrom J.B., Libhaber E., Tshani W., et al. Reversal of IFN-gamma, oxLDL and prolactin serum levels correlate with clinical improvement in patients with peripartum cardiomyopathy. Eur J Heart Fail 10 (2008) 861-868
30. Cohen M., Meisser A., and Bischof P. Metalloproteinases and human placental invasiveness. Placenta 27 (2006) 783-793
31. Weiss A., Goldman S., and Shalev E. The matrix metalloproteinases (MMPS) in the decidua and fetal membranes. Front Biosci 12 (2007) 649-659
32. Macotela Y., Aguilar M.B., Guzman-Morales J., Rivera J.C., Zermeno C., Lopez-Barrera F., et al. Matrix metalloproteases from chondrocytes generate an antiangiogenic 16 kDa prolactin. J Cell Sci 119 (2006) 1790-1800
33. Horrobin D.F. The possible role of prolactin in pre-eclampsia. Med Hypotheses 1 (1975) 159-164
34. Parra A., and Ramirez-Peredo J. The possible role of prolactin in preeclampsia: 2001, a hypothesis revisited a quarter of century later. Med Hypotheses 59 (2002) 378-384
35. Myatt L., and Webster R.P. Vascular biology of preeclampsia. J Thromb Haemost 7 (2009) 375-384
36. Cnossen J.S., Vollebregt K.C., de Vrieze N., ter Riet G., Mol B.W., et al. Accuracy of mean arterial pressure and blood pressure measurements in predicting pre-eclampsia: systematic review and meta-analysis. BMJ 336 (2008) 1117-1120
37. Kim Y.H., Hwang H.S., Kim Y.T., Kim H.S., and Park Y.W. Modulation of matrix metalloproteinase secretion by adenosine A3 receptor in preeclamptic villous explants. Reprod Sci 15 (2008) 939-949
38. Cockle J.V., Gopichandran N., Walker J.J., Levene M.I., and Orsi N.M. Matrix metalloproteinases and their tissue inhibitors in preterm perinatal complications. Reprod Sci 14 (2007) 629-645
39. Montagnana M., Lippi G., Albiero A., Scevarolli S., Salvagno G.L., Franchi M., et al. Evaluation of metalloproteinases 2 and 9 and their inhibitors in physiologic and pre-eclamptic pregnancy. J Clin Lab Anal 23 (2009) 88-92
40. Myers J.E., Merchant S.J., Macleod M., Mires G.J., Baker P.N., and Davidge S.T. MMP-2 levels are elevated in the plasma of women who subsequently develop preeclampsia. Hypertens Pregnancy 24 (2005) 103-115
41. Poon L.C., Nekrasova E., Anastassopoulos P., Livanos P., and Nicolaides K.H. First-trimester maternal serum matrix metalloproteinase-9 (MMP-9) and adverse pregnancy outcome. Prenat Diagn 29 (2009) 553-559
42. Gonzalez C., Parra A., Ramirez-Peredo J., Garcia C., Rivera J.C., Macotela Y., et al. Elevated vasoinhibins may contribute to endothelial cell dysfunction and low birth weight in preeclampsia. Lab Invest 87 (2007) 1009-1017
43. Lamblin N., Bauters C., Hermant X., et al. Polymorphisms in the promoter regions of MMP-2, MMP-3, MMP-9 and MMP-12 genes as determinants of aneurysmal coronary artery disease. J Am Coll Cardiol 40 (2002) 43-48
44. Jahns B.G., Stein W., Hilfiker-Kleiner D., Pieske B., and Emons G. Peripartum cardiomyopathy--a new treatment option by inhibition of prolactin secretion. Am J Obstet Gynecol 199 (2008) e5-e6
45. de Jong J.S., Rietveld K., van Lochem L.T., and Bouma B.J. Rapid left ventricular recovery after cabergoline treatment in a patient with peripartum cardiomyopathy. Eur J Heart Fail 11 (2009) 220-222
46. Habedank D., Kuhnle Y., Elgeti T., Dudenhausen J.W., Haverkamp W., and Dietz R. Recovery from peripartum cardiomyopathy after treatment with bromocriptine. Eur J Heart Fail 10 (2008) 1149-1151
47. Kast R.E., and Altschuler E.L. Dopamine agonists and valvular heart disease. N Engl J Med 356 (2007) 1677-1680